81 FR 41588 - National Eye Institute; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 81, Issue 123 (June 27, 2016)

Page Range		41588-41588
FR Document		2016-15063

Federal Register, Volume 81 Issue 123 (Monday, June 27, 2016)

[Federal Register Volume 81, Number 123 (Monday, June 27, 2016)]
[Notices]
[Page 41588]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-15063]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Eye Institute; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Eye Institute Special Emphasis 
Panel; NEI Clinical Cooperative Agreement and Clinically-Oriented 
Applications.
    Date: July 28, 2016.
    Time: 1:00 p.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, 5635 Fisher Lane, 
Rockville, MD 20814 (Telephone Conference Call).
    Contact Person: Brian Hoshaw, Ph.D., Scientific Review Officer, 
National Eye Institute, National Institutes of Health, Division of 
Extramural Research, 5635 Fishers Lane, Suite 1300, Rockville, MD 
20892, 301-451-2020, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.867, 
Vision Research, National Institutes of Health, HHS)

    Dated: June 21, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-15063 Filed 6-24-16; 8:45 am]
 BILLING CODE 4140-01-P

41588 Federal Register / Vol. 81, No. 123 / Monday, June 27, 2016 / Notices

Health, 6701 Rockledge Drive, Room 4196, DEPARTMENT OF HEALTH AND and 37 CFR part 404 to achieve
MSC 7812, Bethesda, MD 20892; 301–435– HUMAN SERVICES expeditious commercialization of
2902; gubina@csr.nih.gov. results of federally-funded research and
(Catalogue of Federal Domestic Assistance National Institutes of Health development. Foreign patent
Program Nos. 93.306, Comparative Medicine; applications are filed on selected
93.333, Clinical Research, 93.306, 93.333, National Eye Institute; Notice of Closed inventions to extend market coverage
93.337, 93.393–93.396, 93.837–93.844, Meeting for companies and may also be available
93.846–93.878, 93.892, 93.893, National Pursuant to section 10(d) of the for licensing and/or co-development.
Institutes of Health, HHS) Federal Advisory Committee Act, as ADDRESSES: Invention Development and
Dated: June 21, 2016. amended (5 U.S.C. App.), notice is Marketing Unit, Technology Transfer
Natasha M. Copeland, hereby given of the following meeting. Center, National Cancer Institute, 9609
The meeting will be closed to the Medical Center Drive, Mail Stop 9702,
Program Analyst, Office of Federal Advisory
public in accordance with the Rockville, MD 20850–9702.
Committee Policy.
provisions set forth in sections FOR FURTHER INFORMATION CONTACT:
[FR Doc. 2016–15055 Filed 6–24–16; 8:45 am]
552b(c)(4) and 552b(c)(6), title 5 U.S.C., Information on licensing and co-
BILLING CODE 4140–01–P
as amended. The grant applications and development research collaborations,
the discussions could disclose and copies of the U.S. patent
confidential trade secrets or commercial applications listed below may be
DEPARTMENT OF HEALTH AND property such as patentable material, obtained by contacting: Attn. Invention
HUMAN SERVICES and personal information concerning Development and Marketing Unit,
individuals associated with the grant Technology Transfer Center, National
National Institutes of Health
applications, the disclosure of which Cancer Institute, 9609 Medical Center
National Eye Institute; Notice of Closed would constitute a clearly unwarranted Drive, Mail Stop 9702, Rockville, MD
Meeting invasion of personal privacy. 20850–9702, Tel. 240–276–5515 or
Name of Committee: National Eye Institute email ncitechtransfer@mail.nih.gov. A
Pursuant to section 10(d) of the Special Emphasis Panel; NEI Clinical signed Confidential Disclosure
Federal Advisory Committee Act, as Cooperative Agreement and Clinically- Agreement may be required to receive
amended (5 U.S.C. App.), notice is Oriented Applications. copies of the patent applications.
Date: July 28, 2016. SUPPLEMENTARY INFORMATION:
hereby given of the following meeting. Time: 1:00 p.m. to 3:00 p.m. Technology description follows.
The meeting will be closed to the Agenda: To review and evaluate grant
Title of invention: Anti- B-Cell
public in accordance with the applications.
Place: National Institute of Health, 5635 Maturation Antigen Antibodies for
provisions set forth in sections Developing Cancer Therapeutics
Fisher Lane, Rockville, MD 20814
552b(c)(4) and 552b(c)(6), title 5 U.S.C., (Telephone Conference Call). Keywords: BCMA, Antibody,
as amended. The grant applications and Contact Person: Brian Hoshaw, Ph.D., Immunotoxin, Chimeric Antigen
the discussions could disclose Scientific Review Officer, National Eye Receptor (CAR), Antibody-drug
confidential trade secrets or commercial Institute, National Institutes of Health, Conjugate (ADC), Bispecific Antibody,
property such as patentable material, Division of Extramural Research, 5635 Cancer, Myeloma,
and personal information concerning Fishers Lane, Suite 1300, Rockville, MD Description of Technology: Multiple
20892, 301–451–2020, hoshawb@ Myeloma is a subtype of leukemia that
individuals associated with the grant
mail.nih.gov.
applications, the disclosure of which originates in bone marrow, where
(Catalogue of Federal Domestic Assistance normal plasma cells are produced.
would constitute a clearly unwarranted Program Nos. 93.867, Vision Research,
invasion of personal privacy. Although FDA-approved antibody-based
National Institutes of Health, HHS)
therapy is available for other B-cell
Name of Committee: National Eye Institute Dated: June 21, 2016. malignancies, no effective antibody-
Special Emphasis Panel; NEI Data Analysis Natasha M. Copeland, based therapies are available for MM
and Epidemiology Grant Applications.
Program Analyst, Office of Federal Advisory due to the lack of specific target antigen
Date: July 18–19, 2016. Committee Policy. on MM cells. BCMA (B-Cell Maturation
Time: 8:00 a.m. to 5:00 p.m.
[FR Doc. 2016–15063 Filed 6–24–16; 8:45 am] Antigen), is a membrane antigen
Agenda: To review and evaluate grant
BILLING CODE 4140–01–P selectively expressed on mature B-
applications.
lymphocytes and in all MM cells from
Place: National Institutes of Health, 5635
patients. Thus, BCMA shows promise as
Fishers Lane, Bethesda, MD 20892, (Virtual
DEPARTMENT OF HEALTH AND a target for immune-based therapy.
Meeting).
HUMAN SERVICES This technology concerns the
Contact Person: Jeanette M. Hosseini,
generation of several monoclonal
Ph.D., Scientific Review Officer, 5635 Fishers National Institutes of Health
Lane, Suite 1300, Bethesda, MD 20892, 301–
antibodies against BCMA. These
451–2020, jeanetteh@mail.nih.gov.
antibodies can be utilized
Government-Owned Inventions; therapeutically in several ways,
(Catalogue of Federal Domestic Assistance Availability for Licensing including as recombinant
Program Nos. 93.867, Vision Research,
AGENCY: National Institutes of Health, immunotoxins, chimeric antigen
National Institutes of Health, HHS)
receptors (CARs), antibody-drug
mstockstill on DSK3G9T082PROD with NOTICES

HHS.
Dated: June 21, 2016. ACTION: Notice. conjugates (ADCs), bispecific
Natasha M. Copeland, antibodies, and as unconjugated
Program Analyst, Office of Federal Advisory SUMMARY: The invention listed below is antibodies. The antibodies can also be
Committee Policy. co-owned by an agency of the U.S. use in diagnostic applications. It is
[FR Doc. 2016–15061 Filed 6–24–16; 8:45 am] Government and is available for important to note that several
licensing and/or co-development in the conjugated immunotoxins using the
BILLING CODE 4140–01–P
U.S. in accordance with 35 U.S.C. 209 antibodies of this invention have

VerDate Sep<11>2014 18:52 Jun 24, 2016 Jkt 238001 PO 00000 Frm 00081 Fmt 4703 Sfmt 4703 E:\FR\FM\27JNN1.SGM 27JNN1

Document Created: 2016-06-25 02:07:13
Document Modified: 2016-06-25 02:07:13

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		July 28, 2016.
FR Citation		81 FR 41588

81 FR 41588 - National Eye Institute; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 81, Issue 123 (June 27, 2016)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health